Technical Data
E3455-07A1
Erythropoietin, alpha, Recombinant, Human (Liquid) (EPO, EPO-a, EPO-alpha, Epoetin, EP, MGC138142)
5ug
50ug
50ug
|
Technical Data |
|
E3455-07A1 |
Erythropoietin, alpha, Recombinant, Human (Liquid) (EPO, EPO-a, EPO-alpha, Epoetin, EP, MGC138142) |
5ug 50ug |
| Growth Factors, Cytokines | Storage: -70°CShipping: Dry Ice |
|
Erythropoietin, ~34-36kD, normally produced in the kidney and liver, is the principle hormone involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. Indicated for treatment of neutropenia or anemia secondary to ZDV- or Ganciclovir-induced bone marrow suppression (most effective in patients with endogenous EPO levels < 500 IU/ml). Dimers and Aggregates: 1% as determined by silver stained SDS-PAGE gel analysis. Biological Activity: Fully biologically active when compared to standard. Specific Activity (Normocythaemic mice): ~120,000 IU/mg. Storage and Stability: Aliquot to avoid repeated freezing and thawing and freeze at -70°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Aliquots are stable for at least 12 months. Molecular Weight: 34-36kD |
Source: Recombinant Human in Chinese hamster ovary (CHO) cells Purity: Chromatographically purified. 98% by RP-HPLC, Anion-exchange FPLC. Analyzed by reducing and non-reducing SDS-PAGE, Silver Stained. Endotoxin: 0.1ng/ug (IEU/ug) Concentration: ~0.1mg/ml Form: Supplied as a liquid in sodium citrate, sodium chloride, citric acid buffer. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Ford PA, Ford JM, (2004) Transfusion Dec;44(12 Suppl):15S-25S. 2. Wei X, Swanson SJ, (2004) J Immunol Methods Oct;293(1-2):115-26. 3. Godin M, (2004) Soins Sep;(688 Suppl):5. 4. Cervantes F, Alvarez-Larran A, Sureda A, (2004) Br J Haematol Nov 127(4):399-403. 5. Mesjasz J, Wiecek A, Mazur W, (2004) Pol Merkuriusz Lek Apr 16(94):362-7. 6. Bergstrom S, Ahlgren J, (2004) Lakartidningen Oct 7;101(41):3160-1.
|
||